Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study

What Was Tested

The paper reports a study of VIP (Vasoactive Intestinal Peptide), published as a randomized controlled trial.

To study the effect of intracorporeal injection (IC) of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate (PM) on men with erectile dysfunction (ED) of nonpsychogenic aetiology.

Who Took Part

The abstract describes 236 men taking part.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, men only.

The study comprised 236 men with primarily nonpsychogenic ED attending sexual dysfunction clinics at eight institutions.

In a placebo-controlled phase, 171 patients were subsequently treated and self-administered up to 12 injections over a 6-month interval.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this VIP (Vasoactive Intestinal Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind VIP (Vasoactive Intestinal Peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with VIP (Vasoactive Intestinal Peptide) could be set against what happens without it.

The methods mention a period of 6 months.

The main aetiologies of ED were arteriogenic (38), diabetes mellitus (DM) (39), neurogenic (35), mixed (90), and venous leakage (30).

What Was Measured

PubMed files the paper under topics including Impotence, Vasculogenic, Injections, Patient Satisfaction, Penile Erection, Phentolamine, Sympatholytics and Vasoactive Intestinal Peptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of VIP (Vasoactive Intestinal Peptide) in 236 men over 6 months.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (BJU international), a journal based in England.

More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.